The HAWK study (NCT02207530) was a phase II trial evaluating the efficacy and safety of single-agent anti-PD-L1 antibody drug durvalumab in platinum-resistant R/M-HNSCC patients with high PD-L1 expression (≥25%). Here, CD274 is linked to head and neck squamous cell carcinoma.